Fetal Surgery for Congenital Pulmonary Airway Malformation

Fetal Surgery for Congenital Pulmonary Airway Malformation

No Results

No Results


Congenital pulmonary airway malformations (CPAMs) are lung lesions that result from disordered development of the lower respiratory tract. These malformations have a wide spectrum of severity and vary substantially in size and composition. [1]

CPAMs are characterized by airway cysts of varying size that are connected to the tracheobronchial tree. [2]  Although an elaborate postnatal staging system exists, prenatal diagnosis focuses on the size of the lesion—that is, whether the cysts are smaller than 5 mm (microcystic) or larger than 5 mm (macrocystic). [3, 4]

These lesions are almost always unilateral and can be associated with other lung lesions such as bronchopulmonary sequestrations and congenital lobar emphysema. [5, 6, 7]  The vascular supply and drainage from CPAMs is almost always to the pulmonary circulation; however, bronchopulmonary sequestrations may be connected to the systemic circulation.

CPAMs are the most common congenital lung lesion. [8, 9]  Registry data suggest that CPAM affects 1 in 8000-35,000 live births. [2]  This may be an underestimate of the true incidence of the disease, given the existence of nonregistered in-utero mortality, such as the “hidden mortality” that was seen with congenital diaphragmatic hernia. [10]

The cause of CPAM is unknown, but several hypotheses have been advanced. One prevailing theory is that CPAM is caused by airway obstruction. The different presentation and types of lesions are accounted for by the timing and location of obstruction. [2, 11]  It has also been proposed that an imbalance between cell proliferation and apoptosis during airway branching morphogenesis may lead to CPAM. [12, 13]  Dysregulation the genes HOXB5  [14]  and glial cell-derived neurotrophic factor [13]  have also been implicated in CPAM pathogenesis.

The expanded use of prenatal ultrasonography (see the images below) has increased the recognition of CPAMs and has helped characterize their natural history. [5, 8, 9]  Prenatal therapy for CPAM is considered if the affected fetus begins to show signs of hydrops fetalis. [1]  Although the natural history of CPAMs varies, several trends have been described.

Microcystic lesions typically have a rapid growth phase between 20 and 26 weeks’ gestation that usually peaks at about 25 weeks. [15] Subsequently, growth of these lesions plateaus. In many cases, the lesions actually regress, [16, 17] and some disappear completely. [18, 19] Macrocystic lesions may grow rapidly throughout gestation and do not have the characteristic pattern of growth through the late second trimester with subsequent plateau or decrease in size.

Large CPAM lesions that are either microcystic or macrocystic can compress other thoracic structures such as the esophagus, mediastinum, and inferior vena cava (see image below). This compression can result in impaired venous return, polyhydramnios, and hydrops fetalis. The small percentage of CPAMs with this behavior that lead to hydrops are associated with a high mortality, and fetal intervention may be considered in these patients. [1]

Determining which fetuses will develop hydrops is critical to formulating appropriate surveillance and therapeutic strategies. Investigators have used a ratio that compares the calculated volume of the lesion to the fetal head circumference (CPAM volume ratio [CVR]). [20] A CVR of greater than 1.6 suggests hydrops development and warrants close prenatal surveillance. [1, 20]

The use of steroid therapy is clearly indicated for microcystic CPAMs that have resulted in hydrops. [4] There is minimal maternal morbidity associated with this intervention, and efficacy is superior to fetal resection.

Uncertainty remains about nonhydropic fetuses with large microcystic CPAMs. A randomized trial led by the University of California, San Francisco, attempted to address the use of steroids in this context, but recruitment was hampered because of the increasing use of maternal steroids for nonhydropic microcystic CPAMs. In most centers, steroids are administered for microcystic CPAMs with a CVR greater than 1.0. 

Macrocystic lesions are best treated with catheter-based therapies. [1]  Drainage of macrocystic CPAMs decreases the size and compressive effects of CPAMs; it is indicated in lesions that cause hydrops. [21]

Simple cyst aspiration usually precedes thoracoamniotic shunt placement to ensure the efficacy of CPAM fluid removal. [22] Gestational age should be greater than 20 weeks and less than 32 weeks. The risk of chest-wall deformity is extremely high if catheter-based interventions are pursued before 20 weeks. After 32 weeks, delivery and neonatal resection are indicated rather than prenatal therapy.

Shunt choice also changes with gestational age.  Before 24-25 weeks, Harrison shunts (Cook Medical, Bloomington, IN) are preferred because of their smaller size. After 25 weeks, Rocket shunts (Rocket Medical, Hingham, MA) are preferred because of the decreased likelihood of migration and ease of insertion.

Fetal resection of CPAMs is much less common than steroid therapy, owing to the efficacy of maternal steroid administrations. The general consensus is that large microcystic lesions that threaten fetal well-being are best treated with steroid therapy. [23] Macrocystic lesions are best treated with catheter-based therapies. [1] If steroids are ineffective, open fetal resection can be used as salvage therapy.

In rare cases, hydrops and fetal compromise can occur in or persist into the third trimester. In these cases, the CVR is typically greater than 1.6-2.0, and significant respiratory distress is anticipated at birth. The ex-utero intrapartum treatment (EXIT) procedure utilizes the placenta for gas exchange so that the fetal lungs can be bypassed while airway access is gained and lung lesions can be resected.

Contraindications for macrocystic drainage include a predominately solid CPAM, abnormal fetal karyotype, severe fetal cardiac abnormalities or lack of a window for uterine access. Other associated congenital abnormalities may also represent contraindications but need to be considered on a case-by-case basis.

Contraindications for fetal resection include significant maternal operative risk, abnormal fetal karyotype, and fetal cardiac abnormalities. Other associated congenital abnormalities may also represent contraindications but need to be considered on a case-by-case basis.

The EXIT procedure requires maternal laparotomy and hysterotomy. If maternal health is significantly endangered by these interventions, EXIT should not be performed.

Overall survival data for thoracoamniotic shunts for macrocystic CPAM can be derived from the aggregation of several small reports of its use. In a study by Wilson, 26 of the 41 patients treated survived (63%). [21] A large single-center report by Peranteau et al described thoracoamniotic shunt placement in 38 patients with macrocystic lung lesions that were either causing hydrops or believed to be at high risk for causing lung hypoplasia. [24] Hydrops was present in 69% of the population. Overall survival in this group was 73%.

Several investigators have demonstrated a survival rate of approximately 50% for hydropic fetuses with microcystic CPAM after surgery. [1] Hydropic fetuses treated with steroids, however, have survival rates near 85%. [4] The superiority of steroid therapy combined with its complete abrogation of serious maternal risk has made it the standard of care for hydrops caused by microcystic CPAM before 32 weeks’ gestation. If hydrops persists or emerges past 32 weeks, EXIT and neonatal resection remain options. [16, 25]

Adzick NS. Management of fetal lung lesions. Clin Perinatol. 2009 Jun. 36(2):363-76, x. [Medline].

Shanti CM, Klein MD. Cystic lung disease. Semin Pediatr Surg. 2008 Feb. 17(1):2-8. [Medline].

Adzick NS, Harrison MR, Crombleholme TM, Flake AW, Howell LJ. Fetal lung lesions: management and outcome. Am J Obstet Gynecol. 1998 Oct. 179(4):884-9. [Medline].

Curran PF, Jelin EB, Rand L, et al. Prenatal steroids for microcystic congenital cystic adenomatoid malformations. J Pediatr Surg. 2010 Jan. 45(1):145-50. [Medline].

Ankermann T, Oppermann HC, Engler S, Leuschner I, Von Kaisenberg CS. Congenital masses of the lung, cystic adenomatoid malformation versus congenital lobar emphysema: prenatal diagnosis and implications for postnatal treatment. J Ultrasound Med. 2004 Oct. 23(10):1379-84. [Medline].

Cass DL, Crombleholme TM, Howell LJ, Stafford PW, Ruchelli ED, Adzick NS. Cystic lung lesions with systemic arterial blood supply: a hybrid of congenital cystic adenomatoid malformation and bronchopulmonary sequestration. J Pediatr Surg. 1997 Jul. 32(7):986-90. [Medline].

Maas KL, Feldstein VA, Goldstein RB, Filly RA. Sonographic detection of bilateral fetal chest masses: report of three cases. J Ultrasound Med. 1997 Oct. 16 (10):647-52. [Medline].

De Santis M, Masini L, Noia G, Cavaliere AF, Oliva N, Caruso A. Congenital cystic adenomatoid malformation of the lung: antenatal ultrasound findings and fetal-neonatal outcome. Fifteen years of experience. Fetal Diagn Ther. 2000 Jul-Aug. 15(4):246-50. [Medline].

Taguchi T, Suita S, Yamanouchi T, et al. Antenatal diagnosis and surgical management of congenital cystic adenomatoid malformation of the lung. Fetal Diagn Ther. 1995 Nov-Dec. 10(6):400-7. [Medline].

Harrison MR, Bjordal RI, Langmark F, Knutrud O. Congenital diaphragmatic hernia: the hidden mortality. J Pediatr Surg. 1978 Jun. 13(3):227-30. [Medline].

Kunisaki SM, Fauza DO, Nemes LP, et al. Bronchial atresia: the hidden pathology within a spectrum of prenatally diagnosed lung masses. J Pediatr Surg. 2006 Jan. 41(1):61-5; discussion 61-5. [Medline].

Cass DL, Quinn TM, Yang EY, et al. Increased cell proliferation and decreased apoptosis characterize congenital cystic adenomatoid malformation of the lung. J Pediatr Surg. 1998 Jul. 33(7):1043-6; discussion 1047. [Medline].

Fromont-Hankard G, Philippe-Chomette P, Delezoide AL, Nessmann C, Aigrain Y, Peuchmaur M. Glial cell-derived neurotrophic factor expression in normal human lung and congenital cystic adenomatoid malformation. Arch Pathol Lab Med. 2002 Apr. 126(4):432-6. [Medline].

Wilson RD, Hedrick HL, Liechty KW, et al. Cystic adenomatoid malformation of the lung: review of genetics, prenatal diagnosis, and in utero treatment. Am J Med Genet A. 2006 Jan 15. 140(2):151-5. [Medline].

Kunisaki SM, Barnewolt CE, Estroff JA, et al. Large fetal congenital cystic adenomatoid malformations: growth trends and patient survival. J Pediatr Surg. 2007 Feb. 42(2):404-10. [Medline].

Kunisaki SM, Fauza DO, Barnewolt CE, et al. Ex utero intrapartum treatment with placement on extracorporeal membrane oxygenation for fetal thoracic masses. J Pediatr Surg. 2007 Feb. 42(2):420-5. [Medline].

Saltzman DH, Adzick NS, Benacerraf BR. Fetal cystic adenomatoid malformation of the lung: apparent improvement in utero. Obstet Gynecol. 1988 Jun. 71(6 Pt 2):1000-2. [Medline].

MacGillivray TE, Harrison MR, Goldstein RB, Adzick NS. Disappearing fetal lung lesions. J Pediatr Surg. 1993 Oct. 28(10):1321-4; discussion 1324-5. [Medline].

Cavoretto P, Molina F, Poggi S, Davenport M, Nicolaides KH. Prenatal diagnosis and outcome of echogenic fetal lung lesions. Ultrasound Obstet Gynecol. 2008 Nov. 32(6):769-83. [Medline].

Crombleholme TM, Coleman B, Hedrick H, et al. Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. J Pediatr Surg. 2002 Mar. 37(3):331-8. [Medline].

Wilson RD. In utero therapy for fetal thoracic abnormalities. Prenat Diagn. 2008 Jul. 28(7):619-25. [Medline].

Illanes S, Hunter A, Evans M, Cusick E, Soothill P. Prenatal diagnosis of echogenic lung: evolution and outcome. Ultrasound Obstet Gynecol. 2005 Aug. 26(2):145-9. [Medline].

Loh KC, Jelin E, Hirose S, Feldstein V, Goldstein R, Lee H. Microcystic congenital pulmonary airway malformation with hydrops fetalis: steroids vs open fetal resection. J Pediatr Surg. 2012 Jan. 47(1):36-9. [Medline].

Peranteau WH, Adzick NS, Boelig MM, Flake AW, Hedrick HL, Howell LJ, et al. Thoracoamniotic shunts for the management of fetal lung lesions and pleural effusions: a single-institution review and predictors of survival in 75 cases. J Pediatr Surg. 2015 Feb. 50 (2):301-5. [Medline].

Hirose S, Farmer DL, Lee H, Nobuhara KK, Harrison MR. The ex utero intrapartum treatment procedure: Looking back at the EXIT. J Pediatr Surg. 2004 Mar. 39(3):375-80; discussion 375-80. [Medline].

Tsao K, Hawgood S, Vu L, et al. Resolution of hydrops fetalis in congenital cystic adenomatoid malformation after prenatal steroid therapy. J Pediatr Surg. 2003 Mar. 38(3):508-10. [Medline].

Azizkhan RG, Crombleholme TM. Congenital cystic lung disease: contemporary antenatal and postnatal management. Pediatr Surg Int. 2008 Jun. 24(6):643-57. [Medline].

Merchant AM, Peranteau W, Wilson RD, et al. Postnatal chest wall deformities after fetal thoracoamniotic shunting for congenital cystic adenomatoid malformation. Fetal Diagn Ther. 2007. 22(6):435-9. [Medline].

Eric Bradley Jelin, MD Assistant Professor of Surgery, Assistant Professor of Gynecology and Obstetrics, Johns Hopkins University School of Medicine; Director, Fetal Program, Johns Hopkins Children’s Center

Eric Bradley Jelin, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, American Pediatric Surgical Association, Association for Academic Surgery, International Fetal Medicine and Surgery Society

Disclosure: Nothing to disclose.

Angie Child Jelin, MD Assistant Professor of Obstetrics and Gynecology, Johns Hopkins Hospital

Angie Child Jelin, MD is a member of the following medical societies: American Congress of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, Society for Maternal-Fetal Medicine, Society for Reproductive Investigation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Hanmin Lee, MD Professor of Surgery, Pediatrics, Obstetrics/Gynecology and Reproductive Health Sciences, University of California, San Francisco, School of Medicine; Chief, Division of Pediatric Surgery, Director, Fetal Treatment Center, Michael R Harrison, MD, Endowed Chair in Fetal Surgery, Surgeon-in-Chief, UCSF Benioff Children’s Hospital

Hanmin Lee, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, American Pediatric Surgical Association, Association for Academic Surgery, Society of American Gastrointestinal and Endoscopic Surgeons, Society of University Surgeons, International Pediatric Endosurgery Group

Disclosure: Nothing to disclose.

Fetal Surgery for Congenital Pulmonary Airway Malformation

Research & References of Fetal Surgery for Congenital Pulmonary Airway Malformation|A&C Accounting And Tax Services

28 Replies to “Fetal Surgery for Congenital Pulmonary Airway Malformation”

  1. Pingback: pharmacy online
  2. Pingback: cvs pharmacy
  3. Pingback: Buy cheap cialis
  4. Pingback: Cialis in usa
  5. Pingback: levitra pills
  6. Pingback: online levitra
  7. Pingback: online viagra
  8. Pingback: slot games online
  9. Pingback: tadalafil cialis
  10. Pingback: personal loan
  11. Pingback: cash loan
  12. Pingback: viagra cost
  13. Pingback: cialis to buy
  14. Pingback: best casino usa
  15. Pingback: play casino online
  16. Pingback: buy cialis
  17. Pingback: cialis generic
  18. Pingback: cialis to buy

Leave a Reply